SILO Earnings Silo Pharma, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–31 of 31
| Q2 2026 | 2026-06-30 | -2.46 | 2026-08-13 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.12 | 2026-05-14 | 10-Q |
| FY 2025 | 2025-12-31 | -0.50 | 2026-03-27 | 10-K |
| Q3 2025 | 2025-09-30 | -0.50 | 2025-11-13 | 10-Q |
| Q2 2026 | 2025-06-30 | -6.22 | 2026-08-13 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.23 | 2026-05-14 | 10-Q |
| FY 2025 | 2024-12-31 | -1.19 | 2026-03-27 | 10-K |
| Q3 2025 | 2024-09-30 | -0.78 | 2025-11-13 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.59 | 2025-08-13 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.28 | 2025-05-09 | 10-Q |
| FY 2024 | 2023-12-31 | -1.20 | 2025-03-28 | 10-K |
| Q3 2024 | 2023-09-30 | -0.82 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.61 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.29 | 2024-05-13 | 10-Q |
| Q3 2022 | 2022-09-30 | -1.13 | 2022-11-10 | 10-Q |
| Q2 2022 | 2022-06-30 | 0.00 | 2022-08-01 | 10-Q |
| Q1 2022 | 2022-03-31 | 0.00 | 2022-05-13 | 10-Q |
| FY 2021 | 2021-12-31 | 0.04 | 2022-03-28 | 10-K |
| Q3 2022 | 2021-09-30 | 1.78 | 2022-11-10 | 10-Q |
| Q2 2022 | 2021-06-30 | 0.00 | 2022-08-01 | 10-Q |
| Q1 2022 | 2021-03-31 | 0.00 | 2022-05-13 | 10-Q |
| FY 2021 | 2020-12-31 | -0.05 | 2022-03-28 | 10-K |
| Q3 2021 | 2020-09-30 | -0.04 | 2021-11-10 | 10-Q |
| Q3 2019 | 2019-09-30 | -0.03 | 2019-11-13 | 10-Q |
| Q2 2019 | 2019-06-30 | -0.02 | 2019-08-13 | 10-Q |
| Q1 2019 | 2019-03-31 | -0.01 | 2019-05-14 | 10-Q |
| FY 2018 | 2018-12-31 | -0.02 | 2019-04-04 | 10-K |
| Q3 2019 | 2018-09-30 | -0.01 | 2019-11-13 | 10-Q |
| Q2 2019 | 2018-06-30 | -0.01 | 2019-08-13 | 10-Q |
| Q1 2019 | 2018-03-31 | 0.00 | 2019-05-14 | 10-Q |
| FY 2018 | 2017-12-31 | 0.01 | 2019-04-04 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.